Dissemination and Implementation Program in Hypertension in Rwanda: Report on Initial Training and Evaluation.
Journal
Global heart
ISSN: 2211-8179
Titre abrégé: Glob Heart
Pays: England
ID NLM: 101584391
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
27
05
2019
accepted:
03
06
2019
entrez:
21
7
2019
pubmed:
22
7
2019
medline:
29
1
2020
Statut:
ppublish
Résumé
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide and in low- and middle-income countries, and hypertension (HTN) is a major risk factor for CVD. Although effective evidence-based interventions for control of HTN in high-income countries exist, implementation of these in low- and middle-income countries has been challenging due to limited capacity and infrastructure for late-phase translational research. In Rwanda, the 2015 STEPS NCD (STEPwise Approach to Surveillance of Noncommunicable Diseases) risk survey reported an overall prevalence of HTN of 15% (95% confidence interval [CI]: 13.8 to 16.3) for those ages 15 to 64 years; prevalence increased with increasing age to 39% (95% CI: 35.7 to 43.1) for those ages 55 to 64 years; CVD was the third most common cause of mortality (7%). Suboptimal infrastructure and capacity in Rwanda hinders research and community knowledge for HTN control. To address the issue of suboptimal capacity to implement evidence-based interventions in HTN, this project was designed with the following objectives: 1) to develop a regional needs assessment of infrastructure for dissemination and implementation (D & I) strategies for HTN-CVD control; 2) to develop HTN-CVD research capacity through creation of countrywide resources such as core research facilities and training in the fields of HTN-CVD, D & I, and biostatistics; and 3) to engage and train multiple stakeholders in D & I and HTN-CVD evidence-based interventions. A weeklong training program in HTN-CVD, biostatistics, and D & I was conducted in Rwanda in August 2018, and pre- and post-D & I training competency questionnaires were administered. Questionnaire results show a statistically significant increase in D & I knowledge and skills as a result of training (full scale pre- to post-test scores: 2.12 ± 0.78 vs. 3.94 ± 0.42; p < 0.0001). Using principles of community engagement and train-the-trainer methods, we will continue to adapt guidelines and treatments for HTN-CVD developed in high-income countries to the context of Rwanda with the goal of establishing a sustainable platform to address the burden of disease from HTN-CVD.
Sections du résumé
BACKGROUND
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide and in low- and middle-income countries, and hypertension (HTN) is a major risk factor for CVD. Although effective evidence-based interventions for control of HTN in high-income countries exist, implementation of these in low- and middle-income countries has been challenging due to limited capacity and infrastructure for late-phase translational research. In Rwanda, the 2015 STEPS NCD (STEPwise Approach to Surveillance of Noncommunicable Diseases) risk survey reported an overall prevalence of HTN of 15% (95% confidence interval [CI]: 13.8 to 16.3) for those ages 15 to 64 years; prevalence increased with increasing age to 39% (95% CI: 35.7 to 43.1) for those ages 55 to 64 years; CVD was the third most common cause of mortality (7%). Suboptimal infrastructure and capacity in Rwanda hinders research and community knowledge for HTN control.
OBJECTIVES
To address the issue of suboptimal capacity to implement evidence-based interventions in HTN, this project was designed with the following objectives: 1) to develop a regional needs assessment of infrastructure for dissemination and implementation (D & I) strategies for HTN-CVD control; 2) to develop HTN-CVD research capacity through creation of countrywide resources such as core research facilities and training in the fields of HTN-CVD, D & I, and biostatistics; and 3) to engage and train multiple stakeholders in D & I and HTN-CVD evidence-based interventions.
METHODS
A weeklong training program in HTN-CVD, biostatistics, and D & I was conducted in Rwanda in August 2018, and pre- and post-D & I training competency questionnaires were administered.
RESULTS
Questionnaire results show a statistically significant increase in D & I knowledge and skills as a result of training (full scale pre- to post-test scores: 2.12 ± 0.78 vs. 3.94 ± 0.42; p < 0.0001).
CONCLUSIONS
Using principles of community engagement and train-the-trainer methods, we will continue to adapt guidelines and treatments for HTN-CVD developed in high-income countries to the context of Rwanda with the goal of establishing a sustainable platform to address the burden of disease from HTN-CVD.
Identifiants
pubmed: 31324367
pii: S2211-8160(19)30085-7
doi: 10.1016/j.gheart.2019.06.001
pmc: PMC6816501
mid: NIHMS1055703
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
135-141Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK056341
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI025903
Pays : United States
Organisme : NHLBI NIH HHS
ID : U24 HL136790
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States
Informations de copyright
Copyright © 2019. Published by Elsevier B.V.
Références
Hypertension. 2017 Jan;69(1):5-10
pubmed: 27849567
N Engl J Med. 1990 May 31;322(22):1561-6
pubmed: 2139921
Circulation. 2015 Sep 29;132(13):1270-82
pubmed: 26408271
BMJ Open. 2013 Aug 30;3(8):e003423
pubmed: 23996822
J Hum Hypertens. 2010 Dec;24(12):786-95
pubmed: 20220771
Lancet. 2015 Jan 10;385(9963):117-71
pubmed: 25530442
Med Care Res Rev. 2012 Apr;69(2):123-57
pubmed: 22203646
Br J Gen Pract. 2007 Dec;57(545):948-52
pubmed: 18252069
Arch Intern Med. 2005 Apr 25;165(8):923-8
pubmed: 15851645
PLoS One. 2018 Jan 31;13(1):e0191943
pubmed: 29385203
Hypertension. 2009 Sep;54(3):509-15
pubmed: 19597042
Implement Sci. 2015 Aug 07;10:109
pubmed: 26249843
Glob Soc Welf. 2019 Sep;6(3):199-207
pubmed: 32095423
Health Res Policy Syst. 2017 Sep 15;15(1):79
pubmed: 28915890
N Engl J Med. 1996 Jan 4;334(1):13-8
pubmed: 7494564
CMAJ. 2015 Feb 3;187(2):116-119
pubmed: 25316899
Implement Sci. 2013 Aug 19;8:90
pubmed: 23958445
Yearb Med Inform. 2000;(1):65-70
pubmed: 27699347
Hypertension. 2004 Oct;44(4):398-404
pubmed: 15326093
JAMA. 1999 Oct 20;282(15):1458-65
pubmed: 10535437
Med Care. 2012 Mar;50(3):217-26
pubmed: 22310560
Curr Hypertens Rep. 2018 May 1;20(5):38
pubmed: 29717393
Implement Sci. 2013 Sep 05;8:105
pubmed: 24007290
Am J Med Sci. 2014 Aug;348(2):139-45
pubmed: 24978148
Implement Sci. 2015 Aug 12;10:114
pubmed: 26264453
Cardiol Clin. 2017 Feb;35(1):99-115
pubmed: 27886793
Ann Intern Med. 2018 Jan 16;168(2):110-120
pubmed: 29277852
Int J Epidemiol. 2014 Feb;43(1):116-28
pubmed: 24505082
Implement Sci. 2018 Aug 6;13(1):107
pubmed: 30081926
CMAJ. 2012 Jan 10;184(1):E49-56
pubmed: 22105752
Lancet. 2017 Jan 7;389(10064):37-55
pubmed: 27863813
Implement Sci. 2015 Feb 12;10:21
pubmed: 25889199
J Behav Health Serv Res. 2017 Apr;44(2):177-194
pubmed: 26289563
Hypertension. 1995 Apr;25(4 Pt 1):587-94
pubmed: 7721402
N Engl J Med. 1997 May 8;336(19):1350-5
pubmed: 9134875
Glob Heart. 2018 Jun;13(2):131-137
pubmed: 29970340
JAMA Cardiol. 2018 Jul 1;3(7):555-556
pubmed: 29800015